Factors influencing pharmaceutical pricing - a scoping review of academic literature in health science

被引:8
作者
Borges dos Santos, Maria Angelica [1 ]
dos Santos Dias, Leticia Lucia [2 ]
Santos Pinto, Claudia Du Bocage [3 ]
da Silva, Rondineli Mendes [4 ]
Serpa Osorio-de-Castro, Claudia Garcia [4 ]
机构
[1] Fundacao Oswaldo Cruz, Escola Nacl Saude Sergio Arouca, Vice Direcao, Escola Governo, Av Brasil,4036 Sala 902, Manguinho, RJ, Brazil
[2] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil
[3] Univ Fed Mato Grosso do Sul INISA UFMS, Inst Integrad Saude, Campo Grande, MS, Brazil
[4] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ Sergio Arouca, Dept Polit Medicamentos & Assistencia Farmaceut, Rio De Janeiro, Brazil
关键词
Medicine price; Government regulation; Review literature as topic; PRICES; COMPETITION; MEDICINES; MARKET; IMPACT; DRUGS; COST; DISCRIMINATION; REIMBURSEMENT; INNOVATION;
D O I
10.1186/s40545-019-0183-0
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
IntroductionPharmaceutical pricing has only recently gained space in mainstream health science literature.ObjectivesBibliometric and content description of health science academic literature and ad hoc analysis of grey literature on factors influencing pharmaceutical pricing on databases commonly accessed by healthcare professionals.MethodsScoping study with no time limits performed in Medline, Scopus and Scielo, and relevant sites and databases for grey literature, using search terms with database-appropriate keywords.ResultsTwo hundred four articles were published in 103 peer-reviewed journals between 1981 and 2016 (last search year). In grey literature 78 documents were retrieved in the final selection. Five key thematic clusters for analysing pharmaceutical pricing emerged: market dynamics, segmented into (i) supply-related, (ii) consumer-related and (iii) product-related; (iv) trading strategies, either buyer's or seller's and (v) regulatory approach. In peer-reviewed literature there is an overall dominance of themes referring to trading strategies and regulatory approaches and a wide thematic cluster scope. Over half of this literature was produced after the year 2010. International agency technical papers make up the most significant contributions of grey literature, with a clear focus on regulatory approaches to pricing and wider consideration of emerging countries. Research lags in the literature on factors affecting pharmaceutical pricing include impacts of financing schemes, market liberalization, internet trading and biosimilars on prices, with insufficient discussion identified for the effects of discounts/rebates, profits and price transparency.ConclusionsInterest in pharmaceutical pricing literature is increasing. Robust evidence-producing study designs for pricing interventions will be a welcome development.
引用
收藏
页数:12
相关论文
共 85 条
  • [1] Adriaen M., 2008, Journal of Generic Medicines, V5, P175, DOI [10.1057/jgm.2008.8, DOI 10.1057/JGM.2008.8]
  • [2] Reducing Branded Prescription Drug Prices: A Review of Policy Options
    Alexander, G. Caleb
    Ballreich, Jeromie
    Socal, Mariana P.
    Karmarkar, Taruja
    Trujillo, Antonio
    Greene, Jeremy
    Sharfstein, Joshua
    Anderson, Gerard
    [J]. PHARMACOTHERAPY, 2017, 37 (11): : 1469 - 1478
  • [3] Ali G. K. M., 2012, Eastern Mediterranean Health Journal, V18, P811
  • [4] NORWAY PIVOTAL ROLE IN REGULATORY HEALTH ECONOMICS AND PHARMACEUTICAL COST CONTAINMENT - WHAT CAN OTHER COUNTRIES LEARN
    ANDERSSON, F
    [J]. HEALTH POLICY, 1992, 21 (01) : 17 - 34
  • [5] Angrist J., 2010, The credibility revolution in empirical economics: How better research design is taking the con out of econometrics
  • [6] [Anonymous], 1990, Price Theory: An Intermediate Text
  • [7] [Anonymous], 1997, CAN GUID EC EV PHARM
  • [8] Arksey H., 2005, INT J SOC RES METHOD, V8, P19, DOI [10.1080/1364557032000119616, DOI 10.1080/1364557032000119616]
  • [9] Babar Z.-Ud-Din, 2015, Pharmaceutical prices in the 21st century
  • [10] COMPETITION, INNOVATION AND REGULATION IN THE PHARMACEUTICAL-INDUSTRY
    BACKHAUS, J
    [J]. MANAGERIAL AND DECISION ECONOMICS, 1983, 4 (02) : 107 - 121